Report of adverse events of special interest (AESIs) for sintilimab plus a bevacizumab biosimilar (IBI305) in unresectable hepatocellular carcinoma. A multicenter study to investigate the role of ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果